Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: cytarabine

« Back to Dashboard

Summary for Generic Name: cytarabine

Tradenames:3
Patents:1
Applicants:7
NDAs:15
Drug Master File Entries: see list16
Suppliers: see list1

Pharmacology for Ingredient: cytarabine

Clinical Trials for: cytarabine

Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Status: Recruiting Condition: Leukemia

Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
Status: Completed Condition: Acute Myelogenous Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia

AC220 With 5-Aza or Low Dose Cytarabine
Status: Recruiting Condition: Leukemia

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
Status: Recruiting Condition: Leukemia

Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation
Status: Recruiting Condition: Acute Myeloid Leukemia

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
Status: Completed Condition: Richter's Transformation; Leukemia

Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML
Status: Completed Condition: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myeloid Leukemia

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Status: Active, not recruiting Condition: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia

Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)
Status: Suspended Condition: Acute Lymphoblastic Leukemia

Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)
Status: Active, not recruiting Condition: Leukemia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Onco Therapies Ltd
CYTARABINE
cytarabine
INJECTABLE;INJECTION201784Jan 30, 2012RXNo<disabled><disabled>
Eurohlth Intl
CYTARABINE
cytarabine
INJECTABLE;INJECTION071472Aug 2, 1989RXNo<disabled><disabled>
Hospira
CYTARABINE
cytarabine
INJECTABLE;INJECTION072168Aug 31, 1990RXYes<disabled><disabled>
Onco Therapies Ltd
CYTARABINE
cytarabine
INJECTABLE;INJECTION200916Dec 13, 2011RXNo<disabled><disabled>
Teva Parenteral
CYTARABINE
cytarabine
INJECTABLE;INJECTION016793Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc